Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Operating Leases: 2020-2025

Historic Operating Leases for Arrowhead Pharmaceuticals (ARWR) over the last 6 years, with Sep 2025 value amounting to $111.4 million.

  • Arrowhead Pharmaceuticals' Operating Leases rose 0.34% to $111.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.4 million, marking a year-over-year increase of 0.34%. This contributed to the annual value of $111.4 million for FY2025, which is 0.34% up from last year.
  • Arrowhead Pharmaceuticals' Operating Leases amounted to $111.4 million in FY2025, which was up 0.34% from $111.0 million recorded in FY2024.
  • Arrowhead Pharmaceuticals' Operating Leases' 5-year high stood at $111.4 million during FY2025, with a 5-year trough of $23.3 million in FY2021.
  • Moreover, its 3-year median value for Operating Leases was $111.0 million (2024), whereas its average is $109.0 million.
  • Data for Arrowhead Pharmaceuticals' Operating Leases shows a peak YoY skyrocketed of 238.27% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Arrowhead Pharmaceuticals' Operating Leases stood at $23.3 million in 2021, then soared by 238.27% to $78.8 million in 2022, then spiked by 32.75% to $104.6 million in 2023, then climbed by 6.14% to $111.0 million in 2024, then increased by 0.34% to $111.4 million in 2025.